Rheumnow Podcast cover image

The Last Word on JAK Inhibitor Safety and 1133 Study (1.28.2022)

Rheumnow Podcast

00:00

Do Boosters Work in Immunocompromised Patients?

There were more mace events, major adverse cardovasker events etopa group versus the t and f and hipiter group. This was beyond the upper limits of non inferiority, and that's why it gets a higher label. And we're going to end with a discussion of the a oral surveillance study, the 11 33 study, done by feiser in high risk r a patience,. Just published this week, new england journal. If you haven't heard about this study, oral surveillance, or also called 11 33, you must be living under a rock.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app